<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection - Li, L - 2014 | Cochrane Library</title> <meta content="Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection - Li, L - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008439.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection - Li, L - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008439.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008439.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection" name="citation_title"/> <meta content="Lun Li" name="citation_author"/> <meta content="Lanzhou University" name="citation_author_institution"/> <meta content="Jin Hui Tian" name="citation_author"/> <meta content="Lanzhou University" name="citation_author_institution"/> <meta content="KeHu Yang" name="citation_author"/> <meta content="Lanzhou University" name="citation_author_institution"/> <meta content="yangkh@lzu.edu.cn" name="citation_author_email"/> <meta content="Peng Zhang" name="citation_author"/> <meta content="Nanyang Central Hospital" name="citation_author_institution"/> <meta content="Wen Qin Jia" name="citation_author"/> <meta content="Lanzhou University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD008439.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/07/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008439.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008439.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008439.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*CCR5 Receptor Antagonists; Anti‐HIV Agents [*therapeutic use]; Antibodies, Monoclonal [*therapeutic use]; Antibodies, Monoclonal, Humanized [*therapeutic use]; Drug Administration Schedule; HIV Antibodies [*therapeutic use]; HIV Infections [*drug therapy]; HIV‐1 [*genetics]; RNA, Viral [blood]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008439.pub3&amp;doi=10.1002/14651858.CD008439.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008439\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008439\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008439.pub3",title:"Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection",firstPublishedDate:"Jul 26, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane HIV/AIDS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008439.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008439.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008439.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008439.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008439.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008439.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008439.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008439.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008439.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008439.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>759 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008439.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-sec-0076"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/appendices#CD008439-sec-0081"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/table_n/CD008439StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/table_n/CD008439StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information#CD008439-cr-0002">Lun Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information#CD008439-cr-0003">Jin Hui Tian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information#CD008439-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>KeHu Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information#CD008439-cr-0005">Peng Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information#CD008439-cr-0006">Wen Qin Jia</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information/en#CD008439-sec-0091">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 July 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008439.pub3">https://doi.org/10.1002/14651858.CD008439.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008439-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008439-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008439-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008439-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008439-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008439-abs-0001" lang="en"> <section id="CD008439-sec-0001"> <h3 class="title" id="CD008439-sec-0001">Background</h3> <p>PRO 140 (a humanized form of the PA14 antibody, a monoclonal CCR5 antibody) inhibits CCR5‐tropic (R5) type 1 human immunodeficiency virus (HIV). This may be an effective new treatment with the potential to address the limitations of currently available therapies for HIV‐infected patients. </p> </section> <section id="CD008439-sec-0002"> <h3 class="title" id="CD008439-sec-0002">Objectives</h3> <p>We aimed to assess the efficacy, safety, clinical disease progression and immunologic (CD4 count/percentage) and virologic (plasma HIV RNA viral load) markers of PRO 140 for HIV‐infected patients in randomized controlled trials (RCTs) and quasi‐randomized controlled trials (quasi‐RCTs). </p> </section> <section id="CD008439-sec-0003"> <h3 class="title" id="CD008439-sec-0003">Search methods</h3> <p>We searched databases including <i>The Cochrane Central Register of Controlled Trials (The Cochrane Library 2014, Issue 4), MEDLINE (PubMed, January 1966 to April 2014), EMBASE (January 1978 to April 2014) and ISI Web of Knowledge (January 1966 to April 2014)</i>, online trials registries and other sources. We also screened the reference lists of related literature and eligible studies, and presentations from major HIV/AIDS (human immunodeficiency virus/acquired immunodeficiency syndrome) conferences. </p> </section> <section id="CD008439-sec-0004"> <h3 class="title" id="CD008439-sec-0004">Selection criteria</h3> <p>We included RCTs and quasi‐RCTs comparing PRO 140 with placebo or other antiretroviral drugs, or different doses of PRO 140 for individuals infected with HIV. </p> </section> <section id="CD008439-sec-0005"> <h3 class="title" id="CD008439-sec-0005">Data collection and analysis</h3> <p>Two reviewers (L Li and JH Tian) independently screened all retrieved citations and selected eligible studies. Two authors (P Zhang and WQ Jia) independently extracted data. Any disagreements when selecting studies and extracting data were adjudicated by the review mentor (KH Yang). We used Review Manager (RevMan) software for statistical analysis based on an intention‐to‐treat analysis. We examined heterogeneity using the Chi<sup>2</sup> statistic. We regarded I<sup>2</sup> estimates greater than 50% as moderate or high levels of heterogeneity. According to the level of heterogeneity, we used either a fixed or random‐effects model.If significant heterogeneity existed and the reasons could not be found, we reported the results qualitatively. </p> </section> <section id="CD008439-sec-0006"> <h3 class="title" id="CD008439-sec-0006">Main results</h3> <p>We included three trials comparing PRO 140 with placebo in adult patients with HIV infection. Our review indicates that PRO 140 may offer significant dose‐dependent HIV‐1 RNA suppression with tolerable side effects. PRO 140 2 mg/kg, 5 mg/kg, 10 mg/kg, 162 mg weekly, 324 mg biweekly, and 324 mg weekly showed statistically significant differences in the changes of HIV‐1 RNA levels. HIV‐1 RNA levels were reduced by intravenous (IV) infusion of PRO 140 2 mg/kg or 5 mg/kg on day 10, 5 mg/kg or 10 mg/kg on day 12, 162 mg weekly, 324 mg biweekly, or 324 mg weekly on day 22. PRO 140 2 mg/kg, 5 mg/kg, 10 mg/kg, 162 mg weekly, 324 mg biweekly, and 324 mg weekly demonstrated greater antiviral response. PRO 140 324 mg weekly, 5 mg/kg, and 10 mg/kg showed more patients with ≦ 400 copies/mL HIV‐1 RNA. Only PRO 140 5 mg/kg showed greater change in CD4<sup>+</sup> cell count on day eight. Headache, lymphadenopathy, diarrhoea, fatigue, hypertension, nasal congestion and pruritus were reported to be the most frequent adverse events. </p> </section> <section id="CD008439-sec-0007"> <h3 class="title" id="CD008439-sec-0007">Authors' conclusions</h3> <p>Limited evidence from three small trials suggests that PRO 140 might demonstrate potent, short‐term, dose‐dependent, highly significant antiviral activity. However, as the evidence is insufficient, recommendations cannot yet be made. Larger, longer‐term, double‐blind RCTs are required to provide conclusive evidence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008439-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008439-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008439-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008439-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008439-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008439-abs-0004" lang="en"> <h3>PRO 140 for treatment of people with HIV infection</h3> <p>PRO 140 (a humanized form of the PA14 antibody, a monoclonal CCR5 antibody) is a laboratory made antibody that blocks the CCR5 receptor on CD4 cells. By blocking CCR5, PRO 140 prevents the HIV virus from infecting healthy cells. PRO 140 may be an effective new treatment drug because it has the potential to address the limitations of currently available therapies for HIV‐infected patients. PRO 140 has emerged as an important new therapy and has entered testing. </p> <p>We reviewed the efficacy, safety, clinical disease progression and immunologic (CD4 count/percentage) and virologic (plasma HIV RNA viral load) markers of PRO 140 for HIV‐infected patients. We included three randomized controlled trials (RCTs). The evidence is current to April, 2014. These three RCTs were of unclear risk of bias, as the details of methodological items were not adequately reported. All patients in these three studies were adult HIV‐infected patients, PRO 140 was adminstrated subcutaneous or intravenous infusion with different doses. These three studies adressed the immunologic (CD4 count/percentage) and virologic (plasma HIV RNA viral load) markers. There may be potential conflicts of interest in all studies, as some of the authors are current or past employees of Progenics Pharmaceuticals, the producer of PRO 140. </p> <p>Our systematic review showed that PRO 140 may offer significant short‐term dose‐dependent HIV‐1 RNA suppression with tolerable side effects. PRO 140 2 mg/kg, 5 mg/kg, 10 mg/kg, 162 mg weekly, 324 mg biweekly, and 324 mg weekly could reduce HIV‐1 RNA levels and demonstrate antiviral response. And PRO 140 5 mg/kg showed greater change in CD4<sup>+</sup> cell count on day eight. Headache, lymphadenopathy, diarrhoea, fatigue, hypertension, nasal congestion and pruritus were reported to be the most frequent adverse events. Even though available evidence from the three trials suggests that PRO 140 may be effective, the number of patients in these three studies was very small, and the results of these three studies may be influenced by potential biases. So the quality of the evidence from available RCTs was low. </p> <p>PRO 140 has been granted fast‐track approval status by the United States Food and Drug Administration (FDA), but the efficacy of PRO 140 still needs to be proven in large, long‐term high quality RCTs. The three studies reviewed here only evaluated the short‐term (58 or 59 days) efficacy. The long‐term efficacy was not evaluated, and adverse events data were not reported adequately for each group. So any recommendations cannot yet be made for applying this evidence. Whether PRO 140 could be used in clinical practice as first‐line treatment for HIV‐infected patients or not depends on the results of high quality future RCTs. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008439-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008439-sec-0076"></div> <h3 class="title" id="CD008439-sec-0077">Implications for practice</h3> <section id="CD008439-sec-0077"> <p>These three small trials suggested PRO 140 may demonstrate potent, dose‐dependent, highly significant antiviral activity. But the frequency of adverse effects could not be determined from the evidence available. Meanwhile, the methodological quality of these three studies was low, and the number of patients in these three studies was very small, which made the quality of the evidence from available RCTs low. That is why available evidence is not sufficient and conclusive to determine whether PRO 140 was effective in HIV patients or not. Thus, at this stage, we cannot recommend PRO 140 as a therapy for the treatment of HIV patients based on available insufficient evidence. </p> </section> <h3 class="title" id="CD008439-sec-0078">Implications for research</h3> <section id="CD008439-sec-0078"> <p>This review analyses three small, preliminary phase I/IIa clinical trials. Larger, longer‐term, double‐blind, randomized phase IIb and III trials need to be performed in order to determine the potential role of PRO 140 as a therapy for HIV infection and to provide conclusive evidence of the efficacy and safety of PRO 140 for HIV patients. Not only should the short‐term anti‐HIV activity and safety of PRO 140 be evaluated in future studies, but also its long‐term efficacy and safety. The methodological quality of these three trials (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) were too low, and therefore the evidence they produced was also of low quality. As a result, in the future the RCTs related to PRO 140 for HIV‐infected patients should be well conducted (adapting strict randomization, blinding and allocation concealment methods) and transparently reported with a long follow‐up. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008439-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008439-sec-0022"></div> <div class="table" id="CD008439-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">PRO 140 compared to placebo for treatment of people with HIV infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PRO 140 compared to placebo for treatment of people with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients being treated for HIV infection<br/> <b>Intervention:</b> PRO 140<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PRO 140</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 0.5 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 3.00</b> <br/> (0.11 to 83.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>19<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 2 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 27.44</b> <br/> (1.25 to 601.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>19<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 5 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 439.09</b> <br/> (25.73 to 7493.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>40<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 10 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 145.67</b> <br/> (5.3 to 4004.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 162 mg weekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 24.82</b> <br/> (1.17 to 527.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 324 mg weekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 147.00</b> <br/> (5.35 to 4037.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 324 mg biweekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 57.00</b> <br/> (2.59 to 1253.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Randomization: method not specified; Allocation concealment: unclear; Blinding: method not specified.<br/> <sup>2</sup> Total number of events is less than 300. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008439-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">PRO 140 compared to placebo for treatment of people with HIV infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PRO 140 compared to placebo for treatment of people with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients being treated for HIV infection<br/> <b>Intervention:</b> PRO 140<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PRO 140</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg in the control groups was<br/> <b>‐0.39 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg in the intervention groups was<br/> <b>0.19 lower</b> <br/> (0.42 lower to 0.04 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 2 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 2 mg/kg in the control groups was<br/> <b>‐0.39 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 2 mg/kg in the intervention groups was<br/> <b>0.81 lower</b> <br/> (1.22 to 0.4 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 5 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 5mg/kg in the control groups was<br/> <b>‐0.305 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 5 mg/kg in the intervention groups was<br/> <b>1.49 lower</b> <br/> (1.65 to 1.32 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 10 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 10 mg/kg in the control groups was<br/> <b>‐0.32 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 10 mg/kg in the intervention groups was<br/> <b>1.51 lower</b> <br/> (1.8 to 1.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 162 mg weekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 162 mg weekly in the control groups was<br/> <b>‐0.23 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 162 mg weekly in the intervention groups was<br/> <b>0.76 lower</b> <br/> (1.14 to 0.38 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 324 mg weekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 324 mg weekly in the control groups was<br/> <b>‐0.23 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 324 mg weekly in the intervention groups was<br/> <b>1.42 lower</b> <br/> (1.8 to 1.04 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 324 mg biweekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 324 mg biweekly in the control groups was<br/> <b>‐0.23 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 324 mg biweekly in the intervention groups was<br/> <b>1.14 lower</b> <br/> (1.67 to 0.61 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Randomization: method not specified; Allocation concealment: unclear; Blinding: method not specified.<br/> <sup>2</sup> Total population size is less than 400. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008439-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008439-sec-0023"></div> <section id="CD008439-sec-0024"> <h3 class="title" id="CD008439-sec-0024">Description of the condition</h3> <p>Although there have been important advances in preventing new human immunodeficiency virus (HIV) infections and lowering the number of acquired immunodeficiency syndrome (AIDS)‐related deaths, the number of people living with HIV continues to increase. In 2008, the number reached an estimated 33.4 million, which was 20% higher than in 2000; the prevalence was roughly three‐fold higher than it was in 1990 (<a href="./references#CD008439-bbs2-0026" title="UNAIDS2009 . 09 AIDS epidemic update. www.search.unaids.org/search.asp?lg=en&amp;search=09%20AIDS%20epidemic%20update (accessed 18 November 2009). ">UNAIDS 2009</a>). Also in 2008, approximately 2.7 million people became newly infected HIV patients, and about 2 million died from AIDS‐related illnesses worldwide (<a href="./references#CD008439-bbs2-0026" title="UNAIDS2009 . 09 AIDS epidemic update. www.search.unaids.org/search.asp?lg=en&amp;search=09%20AIDS%20epidemic%20update (accessed 18 November 2009). ">UNAIDS 2009</a>;<a href="./appendices#CD008439-sec-0082">Appendix 1</a>). In 2012, there was an estimated 35.3 million people living with HIV, 2.3 million new HIV infections, 1.6 million AIDS deaths in 2012 globally (<a href="./references#CD008439-bbs2-0027" title="UNAIDS2013 . UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf accessed 23 July 2014. ">UNAIDS 2013</a>; <a href="./appendices#CD008439-sec-0082">Appendix 1</a>).The continuing rise in the number of people living with HIV is due to factors such as the beneficial effects of antiretroviral therapy (ART) and population growth. Recent epidemiological data indicated that the spread of HIV appeared to have peaked globally in 1996, when 3.5 million new HIV infections occurred (<a href="./references#CD008439-bbs2-0026" title="UNAIDS2009 . 09 AIDS epidemic update. www.search.unaids.org/search.asp?lg=en&amp;search=09%20AIDS%20epidemic%20update (accessed 18 November 2009). ">UNAIDS 2009</a>). </p> </section> <section id="CD008439-sec-0025"> <h3 class="title" id="CD008439-sec-0025">Description of the intervention</h3> <p>Highly active antiretroviral therapy (HAART) is the main treatment for HIV infection and has significantly demonstrated efficacy in suppressing HIV replication and improving survival of people living with HIV infection and AIDS (<a href="./references#CD008439-bbs2-0020" title="MocroftA , VellaS , BenfieldTL , ChiesiA , MillerV , GargalianosP , et al. EuroSIDA Study Group. Changing patterns of mortality across Europe in patients infected with HIV‐1. Lancet1998;352(9142):1725‐30. ">Mocroft 1998</a>; <a href="./references#CD008439-bbs2-0021" title="PalellaFJJr , DelaneyKM , MoormanAC , LovelessMO , FuhrerJ , SattenGA , et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine1998;338(13):853‐60. ">Palella 1998</a>; <a href="./references#CD008439-bbs2-0022" title="PujariSN , PatelAK , NaikE , PatelKK , DravidA , PatelJK , et al. Effectiveness of generic fixed‐dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. Journal of Acquired Immune Deficiency Syndromes2004;37(5):1566‐9. ">Pujari 2004</a>; <a href="./references#CD008439-bbs2-0025" title="SivadasanA , AbrahamOC , RupaliP , PulimoodSA , RajanJ , RajkumarS , et al. High rates of regimen change due to drug toxicity among a cohort of South Indian adults with HIV infection initiated on generic, first‐line antiretroviral treatment. Journal of the Association of Physicians of India2009;57:384‐8. ">Sivadasan 2009</a>). Antiretroviral agents are drawn from four treatment classes: nucleoside reverse transcriptase inhibitors (NRTI), nonnucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors, and fusion inhibitors (<a href="./references#CD008439-bbs2-0009" title="MurgaJD , FrantiM , PevearDC , MaddonPJ , OlsonWC . Potent antiviral synergy between monoclonal antibody and small‐molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy2006;50(10):3289‐96. ">Murga 2006</a>). Standard ART consists of at least three antiretroviral drugs to maximally suppress the HIV virus and stop the progression of the disease. Although very large reductions in death rates have been seen with use of a potent antiretroviral regimen, there is no cure for HIV infection. Drug toxicity of HAART may be life‐threatening, disfiguring or distressing, thus adversely affecting quality of life and the potential for optimum adherence to antiretroviral therapy. Lack of adherence ultimately leads to the emergence of resistance to antiretroviral drugs, and treatment failure (<a href="./references#CD008439-bbs2-0025" title="SivadasanA , AbrahamOC , RupaliP , PulimoodSA , RajanJ , RajkumarS , et al. High rates of regimen change due to drug toxicity among a cohort of South Indian adults with HIV infection initiated on generic, first‐line antiretroviral treatment. Journal of the Association of Physicians of India2009;57:384‐8. ">Sivadasan 2009</a>). Therefore, new agents and treatment strategies that can be deployed in novel combination regimens need to be developed (<a href="./references#CD008439-bbs2-0009" title="MurgaJD , FrantiM , PevearDC , MaddonPJ , OlsonWC . Potent antiviral synergy between monoclonal antibody and small‐molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy2006;50(10):3289‐96. ">Murga 2006</a>). </p> <p>PRO 140 (a humanized form of the PA14 antibody, a monoclonal CCR5 antibody) is a chemokine receptor CCR5 monoclonal antibody that broadly and potently inhibits CCR5‐tropic (R5) HIV‐1 at concentrations that do not antagonize the natural activity of CCR5 in vitro (<a href="./references#CD008439-bbs2-0011" title="RusertP , KusterH , JoosB , MisselwitzB , GujerC , LeemannC , et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. Journal of Virology2005;79(13):8454‐69. ">Rusert 2005</a>; <a href="./references#CD008439-bbs2-0012" title="ShearerWT , DeVilleJG , SamsonPM , MoyeJHJr , FletcherCV , ChurchJA , et al. Susceptibility of pediatric HIV‐1 isolates to recombinant CD4‐IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). Journal of Allergy and Clinical Immunology2006;118(2):518‐21. ">Shearer 2006</a>). PRO 140 may be an effective new treatment drug because it has the potential to address the limitations of currently available therapies for HIV‐infected patients, including the emergence of multidrug resistant viruses, significant side effects, drug‐drug or drug‐food interactions, and often complex daily treatment regimens (<a href="./references#CD008439-bbs2-0024" title="RichardWK . Progenics Pharmaceuticals' HIV drug, PRO 140, receives FDA fast‐track designation. www.natap.org/2006/HIV/022406_02.htm (accessed 18 June 2009). ">Richard 2006</a>). PRO 140 has emerged as an important target for novel HIV‐1 therapies and has entered testing. In a 39‐person safety and efficacy study (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>), the drug reduced HIV viral loads by an average maximal decrease of 1.83 log<sub>10</sub>, which means that 98.5% of the virus was cleared from patients' blood. As a comparison, Gilead's HIV drug Viread, which received marketing approval in 2001, reduced HIV viral loads by an average of 1.5 log<sub>10</sub> in one early stage trial among previously untreated HIV patients (<a href="./references#CD008439-bbs2-0019" title="LouieM , HoganC , HurleyA , CaptanB , FlahertyJ , LamyP , et al. Determining the relative efficacy of Tenofovir DF using frequent measurements of HIV‐1 RNA during a short course of monotherapy in antiretroviral drug naive individuals. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002. ">Louie 2002</a>). PRO 140 generally was well tolerated at all dose levels in the 39‐person study (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>). The largest individual HIV RNA reductions ranged up to ‐2.5 log<sub>10</sub> among patients receiving both 2 mg/kg and 5 mg/kg doses (<a href="./references#CD008439-bbs2-0017" title="BiswasP , TambussiG , LazzarinA . Access denied? The status of co‐receptor inhibition to counter HIV entry. Expert Opinion on Pharmacotherapy2007;8(7):923‐33. ">Biswas 2007</a>). </p> </section> <section id="CD008439-sec-0026"> <h3 class="title" id="CD008439-sec-0026">How the intervention might work</h3> <p>The basic mechanism of PRO 140 is to stop HIV from entering cells and stop viral replication. Entry of HIV‐1 proceeds through a cascade of events mediated by the HIV‐1 envelope glycoproteins gp120 and gp41. The glycoprotein gp120 sequentially binds CD4 and then CCR5 or another coreceptor molecule, thereby triggering gp41‐mediated fusion of the viral and cellular membranes (<a href="./references#CD008439-bbs2-0009" title="MurgaJD , FrantiM , PevearDC , MaddonPJ , OlsonWC . Potent antiviral synergy between monoclonal antibody and small‐molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy2006;50(10):3289‐96. ">Murga 2006</a>). CCR5 is a requisite fusion coreceptor used by the virus as a portal by which to enter and infect healthy cells. PRO 140 is an anti‐CCR5 monoclonal antibody that potently inhibits HIV‐1 entry and replication at concentrations that do not affect CCR5's chemokine receptor activity in vitro (<a href="./references#CD008439-bbs2-0014" title="TrkolaA , KetasTJ , NagashimaKA , ZhaoL , CilliersT , MorrisL , et al. Potent, broad‐spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of Virology2001;75(2):579‐88. ">Trkola 2001</a>). PRO 140 inhibits entry of HIV into cells by preventing virus‐cell binding at a distinct site on the CCR5 co‐receptor without interfering with the natural activity of CCR5. It binds an extracellular (not a transmembrane) site, inhibiting HIV via a competitive, rather allosteric, mechanism (<a href="./references#CD008439-bbs2-0016" title="AIDSinfo . PRO 140. http://www.aidsinfo.nih.gov/ accessed 23 July 2014. ">AIDS info</a>). </p> </section> <section id="CD008439-sec-0027"> <h3 class="title" id="CD008439-sec-0027">Why it is important to do this review</h3> <p>Although HAART showed improved efficacy in HIV‐infected patients, multidrug resistance or treatment related toxicities are the main problems in the treatment. Therefore, new antiretroviral drugs are needed, such as PRO 140, that have no multidrug resistance or toxicities for HIV‐infected patients. This review is necessary because we must make clear the exact efficacy and safety of PRO 140 for HIV‐infected patients based on available RCTs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008439-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008439-sec-0028"></div> <p>The primary objective of this review was to assess the efficacy and safety of PRO 140 in HIV‐infected patients (including adults and children). The second objective was to assess clinical disease progression and immunologic (CD4 count/percentage) and virologic (plasma HIV RNA viral load) markers of PRO 140. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008439-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008439-sec-0029"></div> <section id="CD008439-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008439-sec-0031"> <h4 class="title">Types of studies</h4> <p>We only included RCTs and quasi‐RCTs. It is impossible for PRO 140 to be administered to HIV‐infected patients in cluster‐randomized trials or cross‐over trials; therefore, we only included individual RCTs with parallel design that compared PRO 140 with placebo or other HIV medications (including other CCR5 antagonists), or different doses for HIV‐infected patients. </p> </section> <section id="CD008439-sec-0032"> <h4 class="title">Types of participants</h4> <p>Individuals infected with HIV regardless of age, race/ethnicity, sexual orientation (gay/homosexual, bisexual, heterosexual), gender identity (including transsexuals), nationality, etc. </p> </section> <section id="CD008439-sec-0033"> <h4 class="title">Types of interventions</h4> <p>PRO 140 administrated intravenously or subcutaneously, as compared with placebo or other antiretroviral drugs, including other CCR5 antagonists such as vicriviroc and the entry inhibitors enfuvirtide and maraviroc. Comparisons between different doses or administrations of PRO 140 were considered. We excluded interventions that combined PRO 140 with other therapies for HIV patients. </p> <p> <ol id="CD008439-list-0001"> <li> <p>PRO 140 versus placebo.</p> </li> <li> <p>Different doses or administrations of PRO 140.</p> </li> <li> <p>PRO 140 versus other HIV medications (including other CCR5 antagonists).</p> </li> </ol> </p> </section> <section id="CD008439-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD008439-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008439-list-0002"> <li> <p>Clinical laboratory results (including change of log<sub>10</sub> HIV RNA viral load from baseline, maximum change in viral load following initiation of treatment, antiviral response which was defined as a ≧ 1.0 log<sub>10</sub> copies/mL reduction in HIV RNA level at any time after treatment, change of CD4<sup>+</sup> cell count from baseline, and other parameters following PRO 140 administration, etc.). </p> </li> <li> <p>Number of subjects with ≦ 400 copies/mL HIV RNA.</p> </li> <li> <p>Survival rates.</p> </li> </ol> </p> </section> <section id="CD008439-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008439-list-0003"> <li> <p>Safety and tolerability parameters (including adverse events).</p> </li> <li> <p>Progression to AIDS.</p> </li> <li> <p>Any death.</p> </li> <li> <p>Quality of life: ability to perform daily activities, cognitive function, etc.</p> </li> </ol> </p> </section> </section> </section> <section id="CD008439-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008439-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched databases including <i>The Cochrane Central Register of Controlled Trials (The Cochrane Library 2014, Issue 4), MEDLINE (PubMed, January 1966 to April 2014), EMBASE (January 1978 to April 2014) and ISI Web of Knowledge (January 1966 to April 2014)</i> for randomized trials in HIV‐infected patients who were treated with PRO 140 to the date of the search. We conducted all searches on 17 May 2010 and updated them on 30 April 2014. We did not impose any language restrictions. We combined the MEDLINE search string with the Cochrane Highly Sensitive Search Strategy for identifying RCTs in all the databases (<a href="./references#CD008439-bbs2-0018" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). The detailed search strategies for each database searched were presented in <a href="./appendices#CD008439-sec-0083">Appendix 2</a>. </p> </section> <section id="CD008439-sec-0039"> <h4 class="title">Searching other resources</h4> <section id="CD008439-sec-0040"> <h5 class="title">Online trial searches</h5> <p>We searched the following databases for ongoing RCTs.</p> <p> <ol id="CD008439-list-0004"> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a>). </p> </li> <li> <p>Current Controlled Trials (http://www.controlled‐trials.com/isrctn/).</p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">http://www.who.int/ictrp/en/</a>). </p> </li> <li> <p>Chinese Clinical Trial Registry (<a href="http://www.chictr.org/" target="_blank">www.chictr.org</a>). </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au/default.aspx" target="_blank">http://www.anzctr.org.au/default.aspx</a>). </p> </li> <li> <p>Clinical Trials Registry ‐ India (CTRI) (http://ctri.nic.in/Clinicaltrials/login.php).</p> </li> <li> <p>Association of the British Pharmaceutical Industry (ABPI) Pharmaceutical Industry Clinical Trials database (http://www.abpi.org.uk/our‐work/library/Pages/default.aspx). </p> </li> </ol> </p> </section> <section id="CD008439-sec-0041"> <h5 class="title">Manual searches</h5> <p>In addition, we searched the reference lists of related literature reviews and eligible articles. We performed a handsearch for abstracts published from 1995 to 2008 for presentations at the International Conference on HIV/AIDS in Africa (ICASA). We also searched abstracts from other important HIV meetings conducted by the Conference on Retroviral and Opportunistic Infections (CROI), European Aids Clinical Society (EACS), and International AIDS Society (IAS). </p> </section> </section> </section> <section id="CD008439-sec-0042"> <h3 class="title" id="CD008439-sec-0042">Data collection and analysis</h3> <section id="CD008439-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Two reviewers (L Li and JH Tian) independently screened all titles and abstracts of the citations identified through the searches. If both reviewers believed that the abstracts were potentially relevant, they screened the full‐text articles independently to determine whether the study was eligible for inclusion or not. We applied inclusion and exclusion criteria using a standard form to determine eligibility based on the types of participants, interventions, outcome measures and study designs to select studies. We rejected studies on initial screening if it could be determined that they were not RCTs or relevant to PRO 140 for HIV infections. We excluded other papers that did not meet the inclusion criteria after applying prespecified eligibility criteria (see <a href="#CD008439-fig-0001">Figure 1</a>). A third review author (KH Yang) was available to resolve any disagreements. </p> <div class="figure" id="CD008439-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008439-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008439-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>In keeping with the guidance of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008439-bbs2-0018" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), we used a standardized study record form in data extraction. Two non‐blinded authors (P Zhang and WQ Jia) independently extracted the data using a standardized data extraction form. We gathered the following information from each included study. </p> <p> <ul id="CD008439-list-0005"> <li> <p>Administrative details ‐ titles, authors, publication, year of publication, volume number, issue number, and page numbers (if published); or titles, conductors, year in which the study was conducted (if not published); and details of other relevant papers. </p> </li> <li> <p>Details of study ‐ study design, inclusion and exclusion criteria, number of participants, characteristics of participants (including age, sex, CD4‐cell count; prior use of antiretroviral drugs); number excluded, number enrolled, number analyzed; dropouts and losses; type, duration, frequency and completeness of follow‐up; country and location of the study. </p> </li> <li> <p>Details of intervention ‐ doses, and routes of administration.</p> </li> <li> <p>Details of outcomes ‐ primary and secondary outcomes.</p> </li> </ul> </p> <p>Any disagreements about data extraction were resolved by the adjudication of a third reviewer (KH Yang). </p> </section> <section id="CD008439-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (L Li and P Zhang) independently assessed the quality of each included trial according to the Cochrane Collaboration's tool for assessing risk of bias (Chapter 8 of <a href="./references#CD008439-bbs2-0018" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved discrepancies through discussion. If there was insufficient information about the study methods, we contacted the first author or the corresponding author for further information. If the trial authors did not respond within four or more weeks, we assessed risk of biases from the available information. We assessed these items as 'low risk' of bias, 'unclear risk' of bias, or 'high risk' of bias (see <a href="./appendices#CD008439-sec-0084">Appendix 3</a>). </p> </section> <section id="CD008439-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>In keeping with the guidance of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008439-bbs2-0018" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), we defined measures of treatment effects as follows. </p> <p>For dichotomous outcomes, results were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). For continuous variables, we used recommended methods to collect and combine the data. We used the mean difference (MD), or a standardized mean difference (SMD) if different scales. For quality of life, we measured it as ordinal data, which was reported qualitatively. </p> </section> <section id="CD008439-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>PRO 140 cannot be administered to HIV‐infected patients in cluster‐randomized trials or cross‐over trials; therefore, we only included individual RCTs with parallel design. As a result, individual participants were the unit of analysis. </p> </section> <section id="CD008439-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We tried our best to contact the authors (by email, telephone or fax when available) of the original studies for missing data. If all the authors of the study did not respond within four or more weeks, we extracted all the available data from the published report. We used sensitivity analyses to explore the impact of missing data in the assessment of treatment effect. If data were missing because of drop‐out of participants or loss to follow‐up, we conducted a primary analysis based on intention‐to‐treat analysis. </p> </section> <section id="CD008439-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined heterogeneity among trials using the Chi<sup>2</sup> statistic on N‐1 degrees of freedom with a significance level of 0.05 and the I<sup>2</sup> statistic. I<sup>2</sup> values of 0% to 40% correspond to heterogeneity which might be important; I<sup>2</sup> values of 30% to 60% correspond to heterogeneity which may represent moderate heterogeneity; I<sup>2</sup> values of 50% to 90% correspond to heterogeneity which may represent substantial heterogeneity; I<sup>2</sup> values of 75% to 100% correspond to heterogeneity which may represent considerable heterogeneity (<a href="./references#CD008439-bbs2-0018" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). For I<sup>2</sup> estimates greater than 50% we regarded them as moderate or high levels of heterogeneity and investigated its causes. If heterogeneity persisted, we presented results separately and reported reasons for persistence as possible. </p> </section> <section id="CD008439-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>If it was possible, we had planned to assess reporting biases by using funnel plots in our review. </p> </section> <section id="CD008439-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We used the Review Manager software (<a href="./references#CD008439-bbs2-0023" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) provided by the Cochrane Collaboration for statistical analysis on an intention‐to‐treat basis. Meta‐analysis was considered to measure the appropriate measure of effect if the search yielded a group of trials sufficiently homogeneous in terms of measured outcomes. According to the level of heterogeneity between trials, we used either fixed‐ or random‐effects models where appropriate, and after careful consideration we pooled the outcomes and examined the differences between the two models. If significant heterogeneity existed and the reasons for heterogeneity could not be found, we reported the results qualitatively. For dichotomous outcomes, we expressed results as ORs with 95% CI. We pooled data using the fixed‐effect model but also considered the random‐effects model to ensure robustness of the model. If there were continuous scales of measurement, we used the MD to assess the effects of treatment, or the SMD if different scales had been used. </p> </section> <section id="CD008439-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were planned to explore possible sources of heterogeneity, including routes of administration, dose, duration of therapy, and the different kinds of patients (adults or children). If significant heterogeneity existed, the causes of heterogeneity would be investigated. If the trends of all subgroups were the same, we would combine the results of subgroup analyses to find the overall trend of the interventions. If not, we would combine the overall results. </p> </section> <section id="CD008439-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses would have been made to explore the influence of possible sources and studies of low methodological quality. If significant heterogeneity had existed after subgroup and sensitivity analysis, at the same time the reasons for heterogeneity could not be found, we would have had to report the results qualitatively. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008439-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008439-sec-0054"></div> <section id="CD008439-sec-0055"> <h3 class="title">Description of studies</h3> <p>(see <a href="./references#CD008439-sec-0095" title="">Characteristics of included studies</a>) </p> <section id="CD008439-sec-0056"> <h4 class="title">Results of the search</h4> <p>After comprehensive searches (conducted on 17 May 2010 and updated on 30 April 2014), we found 381 citations identified through electronic databases (Cochrane Central Register of Controlled Trials (CENTRAL): 75 citations; MEDLINE (PubMed): 31 citations; EMBASE: 213 citations; and ISI Web of Science: 15 citations. We identified additional records (46 citations) through other sources (WHO ICTRP: four citations; ClinicalTrials.gov: 33 citations; Current Controlled Trials: one citation, and reference tracking eight citations). </p> <p>After screening based on titles and abstracts, we identified 17 potential citations for further review, as we excluded 148 citations which were duplicates, 109 citations which were not relevant to PRO 140, 77 citations which were not relevant to HIV/AIDS, and 29 citations which were not clinical trials. We excluded seven citations that were in vitro studies (<a href="./references#CD008439-bbs2-0005" title="KetasTJ , FrankI , KlassePJ , SullivanBM , GardnerJP , SpenlehauerC , et al. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. Journal of Virology2003;77(4):2762‐7. ">Ketas 2003</a>; <a href="./references#CD008439-bbs2-0006" title="KetasTJ , KuhmannSE , PalmerA , ZuritaJ , HeW , AhujaSK , et al. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV‐1 infection of human lymphocytes by CCR5 ligands. Virology2007;364(2):281‐290. ">Ketas 2007</a>; <a href="./references#CD008439-bbs2-0008" title="MorrowK , RosenR , RichterL , EmansA , ForbesA , DayJ , et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. Journal of Womens Health2003;12(7):655‐66. ">Morrow 2003</a>; <a href="./references#CD008439-bbs2-0009" title="MurgaJD , FrantiM , PevearDC , MaddonPJ , OlsonWC . Potent antiviral synergy between monoclonal antibody and small‐molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy2006;50(10):3289‐96. ">Murga 2006</a>; <a href="./references#CD008439-bbs2-0010" title="PugachP , KetasTJ , MichaelE , MooreJP . Neutralizing antibody and anti‐retroviral drug sensitivities of HIV‐1 isolates resistant to small molecule CCR5 inhibitors. Virology2008;377(2):401‐7. ">Pugach 2008</a>; <a href="./references#CD008439-bbs2-0011" title="RusertP , KusterH , JoosB , MisselwitzB , GujerC , LeemannC , et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. Journal of Virology2005;79(13):8454‐69. ">Rusert 2005</a>; <a href="./references#CD008439-bbs2-0012" title="ShearerWT , DeVilleJG , SamsonPM , MoyeJHJr , FletcherCV , ChurchJA , et al. Susceptibility of pediatric HIV‐1 isolates to recombinant CD4‐IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). Journal of Allergy and Clinical Immunology2006;118(2):518‐21. ">Shearer 2006</a>), four citations which were not clinical trials (<a href="./references#CD008439-bbs2-0004" title="BoeseckeC , PettSL . Clinical studies with chemokine receptor‐5 (CCR5)‐inhibitors. Current Opinion in HIV and AIDS2012;7(5):456‐62. ">Boesecke 2012</a>; <a href="./references#CD008439-bbs2-0007" title="KhatibN , DasS . PRO 140‐a novel CCR5 co‐receptor inhibitor. Recent Patents on Anti‐infective Drug Discovery2010;5(1):18‐22. ">Khatib 2010</a>; <a href="./references#CD008439-bbs2-0013" title="TenorioAR . The monoclonal CCR5 antibody PRO‐140: the promise of once‐weekly HIV therapy. Current HIV/AIDS Reports2011;8(1):1‐3. ">Tenorio 2011</a>; <a href="./references#CD008439-bbs2-0014" title="TrkolaA , KetasTJ , NagashimaKA , ZhaoL , CilliersT , MorrisL , et al. Potent, broad‐spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of Virology2001;75(2):579‐88. ">Trkola 2001</a>), and one citation that were not published ( <a href="./references#CD008439-bbs2-0015" title="NCT01272258 . A trial of observed long‐acting, anti‐HIV treatment with a monoclonal CCR5 antibody (PRO 140) as an adjunct to a new, optimized, oral antiretroviral regimen in HIV‐infected injection drug users with viral rebound and documented poor adherence. clinicaltrials.gov/show (http://www.clinicaltrials.gov/ct2/show/NCT01272258?term=NCT01272258&amp;rank=1) accessed 23 July 2014. ">NCT01272258</a>). We have tried to contacted the investigators of the three trials, but they did not respond. We ultimately included three trials (six citations, <a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>). (See <a href="#CD008439-fig-0001">Figure 1</a> for flowchart of screening process). </p> </section> <section id="CD008439-sec-0057"> <h4 class="title">Included studies</h4> <p>We included three RCTs (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>), which fulfilled our inclusion criteria. The characteristics of the included trials are presented in <a href="./references#CD008439-sec-0095" title="">Characteristics of included studies</a>. The baseline characteristics of treated subjects for each study are in <a href="./appendices#CD008439-sec-0085">Appendix 4,</a><a href="./appendices#CD008439-sec-0086">Appendix 5</a> and <a href="./appendices#CD008439-sec-0087">Appendix 6</a>. </p> </section> <section id="CD008439-sec-0058"> <h4 class="title">Excluded studies</h4> <p>Based on titles and abstracts, 148 citations which were duplicates, 109 citations which were not relevant to PRO 140, 77 citations which were not relevant to HIV/AIDS, and 29 citations which were not clinical trials were excluded. Based on full‐texts, we excluded seven citations that were in vitro studies (<a href="./references#CD008439-bbs2-0005" title="KetasTJ , FrankI , KlassePJ , SullivanBM , GardnerJP , SpenlehauerC , et al. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. Journal of Virology2003;77(4):2762‐7. ">Ketas 2003</a>; <a href="./references#CD008439-bbs2-0006" title="KetasTJ , KuhmannSE , PalmerA , ZuritaJ , HeW , AhujaSK , et al. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV‐1 infection of human lymphocytes by CCR5 ligands. Virology2007;364(2):281‐290. ">Ketas 2007</a>; <a href="./references#CD008439-bbs2-0008" title="MorrowK , RosenR , RichterL , EmansA , ForbesA , DayJ , et al. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. Journal of Womens Health2003;12(7):655‐66. ">Morrow 2003</a>; <a href="./references#CD008439-bbs2-0009" title="MurgaJD , FrantiM , PevearDC , MaddonPJ , OlsonWC . Potent antiviral synergy between monoclonal antibody and small‐molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy2006;50(10):3289‐96. ">Murga 2006</a>; <a href="./references#CD008439-bbs2-0010" title="PugachP , KetasTJ , MichaelE , MooreJP . Neutralizing antibody and anti‐retroviral drug sensitivities of HIV‐1 isolates resistant to small molecule CCR5 inhibitors. Virology2008;377(2):401‐7. ">Pugach 2008</a>; <a href="./references#CD008439-bbs2-0011" title="RusertP , KusterH , JoosB , MisselwitzB , GujerC , LeemannC , et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. Journal of Virology2005;79(13):8454‐69. ">Rusert 2005</a>; <a href="./references#CD008439-bbs2-0012" title="ShearerWT , DeVilleJG , SamsonPM , MoyeJHJr , FletcherCV , ChurchJA , et al. Susceptibility of pediatric HIV‐1 isolates to recombinant CD4‐IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). Journal of Allergy and Clinical Immunology2006;118(2):518‐21. ">Shearer 2006</a>), four citations which were not clinical trials (<a href="./references#CD008439-bbs2-0004" title="BoeseckeC , PettSL . Clinical studies with chemokine receptor‐5 (CCR5)‐inhibitors. Current Opinion in HIV and AIDS2012;7(5):456‐62. ">Boesecke 2012</a>; <a href="./references#CD008439-bbs2-0007" title="KhatibN , DasS . PRO 140‐a novel CCR5 co‐receptor inhibitor. Recent Patents on Anti‐infective Drug Discovery2010;5(1):18‐22. ">Khatib 2010</a>; <a href="./references#CD008439-bbs2-0013" title="TenorioAR . The monoclonal CCR5 antibody PRO‐140: the promise of once‐weekly HIV therapy. Current HIV/AIDS Reports2011;8(1):1‐3. ">Tenorio 2011</a>; <a href="./references#CD008439-bbs2-0014" title="TrkolaA , KetasTJ , NagashimaKA , ZhaoL , CilliersT , MorrisL , et al. Potent, broad‐spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Journal of Virology2001;75(2):579‐88. ">Trkola 2001</a>), and one citation that were not published (<a href="./references#CD008439-bbs2-0015" title="NCT01272258 . A trial of observed long‐acting, anti‐HIV treatment with a monoclonal CCR5 antibody (PRO 140) as an adjunct to a new, optimized, oral antiretroviral regimen in HIV‐infected injection drug users with viral rebound and documented poor adherence. clinicaltrials.gov/show (http://www.clinicaltrials.gov/ct2/show/NCT01272258?term=NCT01272258&amp;rank=1) accessed 23 July 2014. ">NCT01272258</a>). See <a href="./references#CD008439-sec-0096" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD008439-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>(see <a href="./references#CD008439-sec-0095" title="">Characteristics of included studies</a>, <a href="#CD008439-fig-0002">Figure 2</a>) </p> <div class="figure" id="CD008439-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008439-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>We tried to contact all the authors of the original studies for information about missing risk of bias data, but they did not respond. We analyzed the studies based on available information. All studies (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) mentioned randomization and double‐blinded, but any details about the methods were not mentioned. Allocation concealment, incomplete outcome data, and selective reporting were also not specified. There may be potential conflicts of interest in all studies (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>), as some of the authors are current or past employees of Progenics Pharmaceuticals, the producer of PRO 140. As such, they may hold stock in the company. </p> <section id="CD008439-sec-0060"> <h4 class="title">Allocation</h4> <p>All studies (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) mentioned randomization, but they did not describe the method in detail. These three studies did not mention allocation concealment. The study authors did not respond to our requests for clarification. </p> </section> <section id="CD008439-sec-0061"> <h4 class="title">Blinding</h4> <p>All studies (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) mentioned blinding, but they did not describe the method in detail. The study authors did not respond to our requests for clarification. </p> </section> <section id="CD008439-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Unclear. The study authors did not respond to our requests for clarification.</p> </section> <section id="CD008439-sec-0063"> <h4 class="title">Selective reporting</h4> <p>Unclear. The study authors did not respond to our requests for clarification.</p> </section> <section id="CD008439-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>There may be potential conflicts of interest in all studies (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>), as some of the authors are current or past employees of Progenics Pharmaceuticals, the producer of PRO 140. The three included studies were supported by the US National Institutes of Health (Public Health Service grant AI066329). </p> </section> </section> <section id="CD008439-sec-0065"> <h3 class="title" id="CD008439-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD008439-tbl-0001"><b>Summary of findings for the main comparison</b> PRO 140 compared to placebo for treatment of people with HIV infection</a>; <a href="./full#CD008439-tbl-0002"><b>Summary of findings 2</b> PRO 140 compared to placebo for treatment of people with HIV infection</a> </p> <section id="CD008439-sec-0066"> <h4 class="title">Antiviral effects</h4> <section id="CD008439-sec-0067"> <h5 class="title">Changes in HIV‐1 RNA level</h5> <p>Single IV infusion of PRO 140 0.5 mg/kg did not show any beneficial effects (MD ‐0.19, 95% CI ‐0.42 to 0.04) in the maximum changes in HIV‐1 RNA level after the 58‐day follow‐up period. The other doses (single IV infusion of PRO 140 2 mg/kg, 5 mg/kg, 10 mg/kg, 162 mg weekly, 324 mg weekly, 324 mg biweekly) showed significantly statistical differences between the subjects who were treated with PRO 140 and patients treated with placebo (<a href="./references#CD008439-fig-0007" title="">Analysis 1.1</a>;<a href="#CD008439-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008439-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.1 Individual nadir changes in HIV‐1 RNA level." data-id="CD008439-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.1 Individual nadir changes in HIV‐1 RNA level. </p> </div> </div> </div> <p>One trial (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>) reported the changes in HIV‐1 RNA levels on day 10. There was not a significantly statistical difference in the reductions of HIV‐1 RNA level on day 10 between patients with single IV infusion of PRO 140 0.5 mg/kg and placebo (MD ‐0.24, 95% CI ‐0.61 to 0.13). The other two doses (single IV infusion of PRO 140 2 mg/kg, 5 mg/kg) showed that PRO 140 significantly reduced HIV‐1 RNA level on day 10 (<a href="./references#CD008439-fig-0008" title="">Analysis 1.2</a>;<a href="#CD008439-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD008439-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.2 Changes in HIV‐1 RNA level on day 10." data-id="CD008439-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.2 Changes in HIV‐1 RNA level on day 10. </p> </div> </div> </div> <p>One trial (<a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) reported the changes in HIV‐1 RNA levels on day 12. The result revealed that single IV infusion of PRO 140 5 mg/kg (MD ‐1.71, 95% CI ‐1.96 to ‐1.46) and 10 mg/kg (MD ‐1.75, 95% CI ‐2.00 to ‐1.50) was associated with reduced HIV‐1 RNA levels on day 12. And the combined results showed that PRO 140 could reduce HIV‐1 RNA levels on day 12 (MD ‐1.73, 95% CI ‐1.91 to ‐1.55) without any statistical heterogeneity among the studies (I<sup>2</sup> = 0%, P = 0.82) (<a href="./references#CD008439-fig-0009" title="">Analysis 1.3</a>; <a href="#CD008439-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD008439-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.3 Changes in HIV‐1 RNA level on day 12." data-id="CD008439-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.3 Changes in HIV‐1 RNA level on day 12. </p> </div> </div> </div> <p>One trial (<a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>) reported the changes in HIV‐1 RNA levels on day 22. All the doses (162 mg weekly, 324 mg biweekly, 324 mg weekly) showed that PRO 140 significantly reduced HIV‐1 RNA levels on day 22. The pooled estimate of PRO 140 in the reductions of HIV‐1 RNA level on day 22 was ‐0.87 (95% CI ‐1.08 to ‐0.66) with a high amount of statistical heterogeneity among the studies (I<sup>2</sup> = 80%, P = 0.007) (<a href="./references#CD008439-fig-0010" title="">Analysis 1.4</a>; <a href="#CD008439-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD008439-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.4 Changes in HIV‐1 RNA level on day 22." data-id="CD008439-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.4 Changes in HIV‐1 RNA level on day 22. </p> </div> </div> </div> <p><b>Antiviral response</b> </p> <p>Antiviral response was defined as a &gt;1.0 log<sub>10</sub> copies/mL reduction in HIV‐1 RNA level at any time after treatment. Single IV infusion of PRO 140 0.5 mg/kg did not show any beneficial antiviral response effects (OR 3.00, 95% CI 0.11 to 83.36). The other doses of PRO 140 (single IV infusion of PRO 140 2 mg/kg, 5 mg/kg, 10 mg/kg, 162 mg weekly; 324 mg weekly; 324 mg biweekly) demonstrated greater antiviral response in PRO 140‐treated patients than those treated with placebo (<a href="./references#CD008439-fig-0011" title="">Analysis 1.5</a>). </p> <p><b>Number of subjects with ≦ 400 copies/mL HIV‐1 RNA</b> </p> <p>There were 0 subjects with ≦ 400 copies/mL HIV‐1 RNA for single IV infusion of PRO 140 0.5 mg/kg in both groups. There were significantly statistical differences in the number of subjects with ≦ 400 copies/mL HIV‐1 RNA between the PRO 140 324 mg weekly (OR 51.00, 95% CI 2.30 to 1129.95), 5 mg/kg (OR 43.99, 95% CI 4.22 to 459.01; I<sup>2</sup> = 49%, P = 0.16), 10 mg/kg (OR 145.67, 95% CI 5.30 to 4004.91) and placebo group. The other three doses (single IV infusion of PRO 140 2 mg/kg, 162 mg weekly, 324 mg biweekly) did not show any beneficial effects in the number of subjects with ≦ 400 copies/mL HIV‐1 RNA (<a href="./references#CD008439-fig-0012" title="">Analysis 1.6</a>). </p> <p><b>Change in CD4<sup>+</sup> cell count</b> </p> <p>As two studies (<a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) did not supply sufficient data of the doses of 162 mg weekly, 324 mg biweekly, 324 mg weekly, 5 mg/kg, and 10 mg/kg, we just analyzed the data of PRO 140 in the doses of 0.5 mg/kg, 2 mg/kg, and 5 mg/kg in the changes of CD4<sup>+</sup> cell count on day eight from the study conducted in 2008 (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>). Only the 5 mg/kg dose of PRO 140 showed greater changes in CD4<sup>+</sup> cell count on day eight than placebo‐treated patients (MD 110.00, 95% CI 3.14 to 216.86) (<a href="./references#CD008439-fig-0013" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD008439-sec-0068"> <h4 class="title">Safety</h4> <p>The authors of the three studies did not report enough information about adverse events for each group. In <a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>, the most frequently reported adverse events were headache in 12 subjects; lymphadenopathy in 11 subjects; and diarrhoea and fatigue in eight subjects. In <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>, the most frequently reported systemic adverse events were diarrhoea (6 of 44), headache (6 of 44), lymphadenopathy (5 of 44), and hypertension (4 of 44). <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a> reported that the most frequently reported systemic adverse events were headache in one subject in the 5 mg/kg group and two subjects in the 10 mg/kg group, nasal congestion in two subjects in the placebo group and one subject in the 10 mg/kg group, and pruritus in three subjects in the placebo group. As sufficient data of adverse events to allow for statistical pooling were lacking, we did not pool the data of adverse events. </p> </section> <section id="CD008439-sec-0069"> <h4 class="title">Other outcomes</h4> <p>Other outcomes (including progression to AIDS, any death, quality of life issues, survival rates) were not reported in these three trials. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008439-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008439-sec-0070"></div> <section id="CD008439-sec-0071"> <h3 class="title" id="CD008439-sec-0071">Summary of main results</h3> <p>This review indicates that PRO 140 might offer significant dose‐dependent HIV‐1 RNA suppression and tolerable side effects. All the doses except single IV infusion of PRO 140 0.5mg/kg (single IV infusion of PRO 140 2 mg/kg, 5 mg/kg, 10 mg/kg, 162 mg weekly, 324 mg biweekly and 324 mg weekly) showed significantly statistical differences in the nadir changes in HIV‐1 RNA level between the two groups. Two doses (single IV infusion of PRO 140 2 mg/kg and 5 mg/kg) showed that PRO 140 significantly reduced HIV‐1 RNA levels on day 10. Two doses (single IV infusion of PRO 140 10 mg/kg and 5 mg/kg) showed that PRO 140 significantly reduced HIV‐1 RNA levels on day 12. The three doses (162 mg weekly, 324 mg biweekly and 324 mg weekly) showed that PRO 140 significantly reduced HIV‐1 RNA levels on day 22. All the doses except single IV infusion of PRO 140 0.5 mg/kg (single IV infusion of PRO 140 2 mg/kg, 5 mg/kg, 10 mg/kg, 162 mg weekly, 324 mg biweekly and 324 mg weekly) demonstrated greater antiviral responses than placebo. Three doses of the PRO 140 group (324 mg weekly, 5 mg/kg, 10 mg/kg) showed more patients with ≦ 400 copies/mL HIV‐1 RNA than placebo‐treated patients. Only the single IV infusion of PRO 140 showed greater changes in CD4<sup>+</sup> cell count on day eight than placebo. </p> <p>The authors of the three studies did not report sufficient information about adverse events for each group. As a result, we did not pool the results. Headache, lymphadenopathy, diarrhoea, fatigue, hypertension, nasal congestion and pruritus were reported to be the most frequent adverse events. </p> </section> <section id="CD008439-sec-0072"> <h3 class="title" id="CD008439-sec-0072">Overall completeness and applicability of evidence</h3> <p>Although PRO 140 has been granted fast‐track approval status by the United States FDA, the efficacy of PRO 140 has not yet been proven in large double‐blind RCTs. The numbers of patients in these three studies (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) were very small, and the results of these three studies may be influenced by potential biases. Their durations of follow‐up were very short, only 58 or 59 days. The long‐time efficacy was not evaluated, and the data of adverse events were not reported adequately in each group. Although available evidnece showed that PRO 140 might offer significant short‐term dose‐dependent HIV‐1 RNA suppression with tolerable side effects, but any recommendations could not be made based on these three studies. Whether PRO 140 could be used in clinical practice as front‐line treatment for HIV‐infected patients or not depends on the effects in the future of large double‐blind RCTs. </p> </section> <section id="CD008439-sec-0073"> <h3 class="title" id="CD008439-sec-0073">Quality of the evidence</h3> <p>All studies (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) mentioned randomization and blinding, but any details about the methods were not found. And allocation concealment, incomplete outcome data, and selective reporting were unclear at the same time. The methodological quality of these three studies was low, as there were so many methodological problems, which may reduce the quality of evidence. The big problem was that there may be potential conflicts of interest in these three studies, which make the research results unreliable and unbelievable. The number of patients in these three studies (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) was very small, and the results of these three studies may be influenced by potential biases. Thus, the quality of the evidence from available RCTs was low (<a href="./full#CD008439-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD008439-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD008439-sec-0074"> <h3 class="title" id="CD008439-sec-0074">Potential biases in the review process</h3> <p>We conducted electronic, online trial and manual searches to search for relevant articles, but there may still have been papers we did not find. This review only includes published data; unpublished data of PRO 140 were not included (although we requested the data from the study authors). As a result, selective biases may exist in our review. </p> </section> <section id="CD008439-sec-0075"> <h3 class="title" id="CD008439-sec-0075">Agreements and disagreements with other studies or reviews</h3> <p>Available published data about PRO 140 in these three studies (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) showed positive results and were consistent with each other. All (<a href="./references#CD008439-bbs2-0001" title="ISRCTN45537485 . Study of intravenous PRO 140 or placebo in adult patients with HIV [A phase Ib, double‐blind, randomized, dose‐cohort escalation study of intravenous PRO 140 or placebo in adult patients with HIV‐1 infection]. Current Controlled Trials (http://controlled‐trials.com/ISRCTN45537485/ISRCTN45537485) accessed 23 July 2014. JacobsonJM , SaagMS , ThompsonMA , FischlMA , LiporaceR , ReichmanRC , et al. Antiviral activity of single‐dose PRO 140, a CCR5 monoclonal antibody, in HIV‐infected adults. Journal of Infectious Diseases2008;198(9):1345‐52. [PUBMED: 18771406] ">Jacobson 2008</a>; <a href="./references#CD008439-bbs2-0002" title="JacobsonJM , ThompsonMA , LalezariJP , SaagMS , ZingmanBS , D'AmbrosioP , et al. Anti‐HIV‐1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. Journal of Infectious Diseases2010;201(10):1481‐7. [PUBMED: 20377413] NCT00642707 . Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV ‐1 Infection. ClinicalTrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00642707?term=NCT00642707&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010a</a>; <a href="./references#CD008439-bbs2-0003" title="JacobsonJM , LalezariJP , ThompsonMA , FichtenbaumCJ , SaagMS , ZingmanBS , et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV‐infected adults. Antimicrobrial Agents and Chemotherapy2010;54(10):4137‐42. [PUBMED: 20660677] NCT00613379 . A phase 2a, randomized, double‐blind, placebo‐controlled study of PRO 140 by intravenous administration in adult subjects with human immunodeficiency virus type 1 infection. clinicaltrials.gov (http://www.clinicaltrials.gov/ct2/show/NCT00613379?term=NCT00613379&amp;rank=1) accessed 23 July 2014. ">Jacobson 2010b</a>) showed that PRO 140 offered the potential for significant dose‐dependent HIV‐1 RNA suppression and infrequent patient self‐administration. Any studies or reviews disagreeing with such results for PRO 140 have not been published. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008439-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008439-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008439-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.1 Individual nadir changes in HIV‐1 RNA level." data-id="CD008439-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.1 Individual nadir changes in HIV‐1 RNA level. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.2 Changes in HIV‐1 RNA level on day 10." data-id="CD008439-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.2 Changes in HIV‐1 RNA level on day 10. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.3 Changes in HIV‐1 RNA level on day 12." data-id="CD008439-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.3 Changes in HIV‐1 RNA level on day 12. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.4 Changes in HIV‐1 RNA level on day 22." data-id="CD008439-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 PRO 140 versus placebo, outcome: 1.4 Changes in HIV‐1 RNA level on day 22. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PRO 140 VS placebo, Outcome 1 Individual nadir changes in HIV‐1 RNA level." data-id="CD008439-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 PRO 140 VS placebo, Outcome 1 Individual nadir changes in HIV‐1 RNA level.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#CD008439-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PRO 140 VS placebo, Outcome 2 Changes in HIV‐1 RNA level on day 10." data-id="CD008439-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 PRO 140 VS placebo, Outcome 2 Changes in HIV‐1 RNA level on day 10.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#CD008439-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PRO 140 VS placebo, Outcome 3 Changes in HIV‐1 RNA level on day 12." data-id="CD008439-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 PRO 140 VS placebo, Outcome 3 Changes in HIV‐1 RNA level on day 12.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#CD008439-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PRO 140 VS placebo, Outcome 4 Changes in HIV‐1 RNA level on day 22." data-id="CD008439-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 PRO 140 VS placebo, Outcome 4 Changes in HIV‐1 RNA level on day 22.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#CD008439-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PRO 140 VS placebo, Outcome 5 Antiviral response." data-id="CD008439-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 PRO 140 VS placebo, Outcome 5 Antiviral response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#CD008439-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PRO 140 VS placebo, Outcome 6 No. of subjects with ≦ 400 copies/mL HIV‐1 RNA." data-id="CD008439-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 PRO 140 VS placebo, Outcome 6 No. of subjects with ≦ 400 copies/mL HIV‐1 RNA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#CD008439-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008439-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/urn:x-wiley:14651858:media:CD008439:CD008439-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_t/tCD008439-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PRO 140 VS placebo, Outcome 7 Change in CD4 cell count on day 8." data-id="CD008439-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 PRO 140 VS placebo, Outcome 7 Change in CD4 cell count on day 8.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#CD008439-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/media/CDSR/CD008439/image_n/nCD008439-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008439-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">PRO 140 compared to placebo for treatment of people with HIV infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PRO 140 compared to placebo for treatment of people with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients being treated for HIV infection<br/> <b>Intervention:</b> PRO 140<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PRO 140</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 0.5 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 3.00</b> <br/> (0.11 to 83.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>19<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 2 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 27.44</b> <br/> (1.25 to 601.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>19<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 5 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 439.09</b> <br/> (25.73 to 7493.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>40<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 10 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 145.67</b> <br/> (5.3 to 4004.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 162 mg weekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 24.82</b> <br/> (1.17 to 527.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 324 mg weekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 147.00</b> <br/> (5.35 to 4037.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Antiviral response: 324 mg biweekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>OR 57.00</b> <br/> (2.59 to 1253.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Randomization: method not specified; Allocation concealment: unclear; Blinding: method not specified.<br/> <sup>2</sup> Total number of events is less than 300. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">PRO 140 compared to placebo for treatment of people with HIV infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008439-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">PRO 140 compared to placebo for treatment of people with HIV infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PRO 140 compared to placebo for treatment of people with HIV infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients being treated for HIV infection<br/> <b>Intervention:</b> PRO 140<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PRO 140</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg in the control groups was<br/> <b>‐0.39 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 0.5 mg/kg in the intervention groups was<br/> <b>0.19 lower</b> <br/> (0.42 lower to 0.04 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 2 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 2 mg/kg in the control groups was<br/> <b>‐0.39 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 2 mg/kg in the intervention groups was<br/> <b>0.81 lower</b> <br/> (1.22 to 0.4 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 5 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 5mg/kg in the control groups was<br/> <b>‐0.305 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 5 mg/kg in the intervention groups was<br/> <b>1.49 lower</b> <br/> (1.65 to 1.32 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 10 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 10 mg/kg in the control groups was<br/> <b>‐0.32 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 10 mg/kg in the intervention groups was<br/> <b>1.51 lower</b> <br/> (1.8 to 1.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 162 mg weekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 162 mg weekly in the control groups was<br/> <b>‐0.23 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 162 mg weekly in the intervention groups was<br/> <b>0.76 lower</b> <br/> (1.14 to 0.38 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 324 mg weekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 324 mg weekly in the control groups was<br/> <b>‐0.23 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 324 mg weekly in the intervention groups was<br/> <b>1.42 lower</b> <br/> (1.8 to 1.04 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Individual nadir changes in HIV‐1 RNA level: 324 mg biweekly</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 324 mg biweekly in the control groups was<br/> <b>‐0.23 copies/</b>mL </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean individual nadir changes in HIV‐1 RNA level: 324 mg biweekly in the intervention groups was<br/> <b>1.14 lower</b> <br/> (1.67 to 0.61 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Randomization: method not specified; Allocation concealment: unclear; Blinding: method not specified.<br/> <sup>2</sup> Total population size is less than 400. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">PRO 140 compared to placebo for treatment of people with HIV infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/full#CD008439-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008439-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PRO 140 VS placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Individual nadir changes in HIV‐1 RNA level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.42, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 2 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐1.22, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐1.65, ‐1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 10 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.51 [‐1.80, ‐1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 162 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.76 [‐1.14, ‐0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 324 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.42 [‐1.80, ‐1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 324 mg biweekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐1.67, ‐0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Changes in HIV‐1 RNA level on day 10 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.61, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 2 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.91 [‐1.23, ‐0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.57 [‐1.91, ‐1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Changes in HIV‐1 RNA level on day 12 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.73 [‐1.91, ‐1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 5mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.71 [‐1.96, ‐1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 10 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.75 [‐2.00, ‐1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Changes in HIV‐1 RNA level on day 22 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐1.08, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 162 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.6 [‐0.87, ‐0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 324 mg biweekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐1.63, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 324 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.36 [‐1.76, ‐0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Antiviral response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.11, 83.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 2 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.44 [1.25, 601.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>439.09 [25.73, 7493.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 10 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>145.67 [5.30, 4004.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 162 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.82 [1.17, 527.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 324 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>147.0 [5.35, 4037.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 324 mg biweekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>57.00 [2.59, 1253.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 No. of subjects with ≦ 400 copies/mL HIV‐1 RNA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 2 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.11, 83.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>43.99 [4.22, 459.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 10 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>145.67 [5.30, 4004.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 162 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.11, 82.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 324 mg biweekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.21, 117.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 324 mg weekly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>51.0 [2.30, 1129.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in CD4 cell count on day 8 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 0.5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.0 [‐100.14, 50.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 2 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [‐100.64, 106.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 5 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>110.0 [3.14, 216.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PRO 140 VS placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008439.pub3/references#CD008439-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008439.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008439-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008439-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008439-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008439\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008439\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008439\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008439\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008439\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008439.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008439.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008439.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008439.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008439.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729030053"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008439.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729030057"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008439.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed2ec4f8af56f',t:'MTc0MDcyOTAzMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 